Shire bags a quick thumbs up for its new­ly won can­cer drug pipeline

Shire is ready to cash in its first can­cer drug chip won in its ac­qui­si­tion of Bax­al­ta.

The biotech com­pa­ny says that the EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use has giv­en it a thumbs up on an ap­pli­ca­tion to mar­ket Onivyde — an irinote­can li­po­some in­jec­tion com­bined with 5-flu­o­rouracil and leu­cov­orin to fight metasta­t­ic pan­cre­at­ic can­cer as a sec­ond-line drug af­ter gem­c­itabine ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.